Weather-Induced FDA Delays Cost STAAR Surgical Company Its Bottom Line
A storm delay doubles Staar Surgical's Q1 FDA costs, leading the company to a loss for the quarter. California-based STAAR Surgical (NSDQ:STAA) swung hard to a 1st-quarter loss after storm-related regulatory delays cost the company its bottom line. Staar went from a 1¢ per diluted share profit during this time last year to a 4¢ loss.
Help employers find you! Check out all the jobs and post your resume.